Replimune to Present at Three Upcoming Investor Conferences
Replimune to Present at Three Upcoming Investor Conferences
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following three conferences:
馬薩諸塞州沃本，2024年3月5日（GLOBE NEWSWIRE）——率先開發新型溶瘤免疫療法的臨床階段生物技術公司Replimune集團公司（納斯達克股票代碼：REPL）今天宣佈，Replimune管理團隊的成員將在以下三個會議上主持和主持投資者會議：
Leerink Partners 2024 Global Biopharma Conference
Date: Tuesday, March 12, 2024
Fireside Chat Time: 2:20 pm EDT
Leerink Partners 2024 全球生物製藥大會
日期：2024 年 3 月 12 日，星期二
爐邊聊天時間：美國東部時間下午 2:20
Jefferies Biotech on the Bay Miami Summit
Date: Wednesday, March 13, 2024
傑富瑞生物科技公司海灣邁阿密峯會
日期：2024 年 3 月 13 日星期三
Barclays 26th Annual Global Healthcare Conference
Date: Thursday, March 14, 2024
Fireside Chat Time: 10:45 am EDT
巴克萊第 26 屆年度全球醫療保健會議
日期：2024 年 3 月 14 日星期四
爐邊聊天時間：美國東部時間上午 10:45
Live webcasts of the Leerink and Barclays fireside chats will be available in the Investors section of Replimune's website at . A replay will be available for 30 days following the conference.
Replimune網站的 “投資者” 欄目將提供Leerink和巴克萊銀行爐邊聊天的網絡直播，網址爲。會議結束後的30天內將提供重播。
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit .
關於 Replimune
總部位於馬薩諸塞州沃本的Replimune Group, Inc. 成立於2015年，其使命是通過率先開發新的溶瘤免疫療法產品組合來改變癌症治療。Replimune 專有的 RpX 平台基於強大的 HSV-1 骨幹，旨在最大限度地提高免疫原性細胞死亡和誘導全身抗腫瘤免疫反應。RpX 平台旨在具有獨特的局部和全身雙重活性，包括直接選擇性病毒介導的腫瘤殺死，從而釋放腫瘤衍生抗原，改變腫瘤微環境以激發強烈而持久的全身反應。預計RpX候選產品將與大多數成熟的和實驗性的癌症治療方式產生協同作用，從而具有多功能性，可以單獨開發或與各種其他治療方案結合使用。欲了解更多信息，請訪問。
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
投資者查詢
克里斯·布林茲
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
媒體查詢
艾琳·戈登伯格
Replimune
917.548.1582
media@replimune.com
譯文內容由第三人軟體翻譯。